A 60-year-old woman had taken ursodeoxycholic acid for more than two years for primary biliary cholangitis, but her liver enzymes stayed high and scans began to show cirrhosis, an enlarged spleen and a little fluid. Roughly 30–40% of PBC patients do not respond to the standard drug. In February 2026 she travelled to Ruijin Hospital Hainan, where Prof. Xie Qing wrote the zone’s first prescription for seladelpar — a PPARδ agonist approved elsewhere but not yet available in mainland China outside Lecheng’s pilot channel.
60 岁的李女士患原发性胆汁性胆管炎，规律服用熊去氧胆酸两年多，碱性磷酸酶始终降不下来，复查还出现了肝硬化、脾大和少量腹水。约 30%–40% 的 PBC 患者对一线药物无效，她就是其中之一。2026 年 2 月，她到乐城瑞金海南医院，谢青教授为她开出了乐城首张 Seladelpar 处方——这款 PPARδ 激动剂在境外已获批，国内尚未上市，只能通过乐城先行先试通道使用。
This page is a short English/Chinese summary of the facts in a patient story published by the Lecheng Administration. Photos are from that publication, credited; a link to the original Chinese article sits at the foot of this page. 本页是对Lecheng Administration发布的一篇患者故事中事实的简短中英摘要。照片取自该发布并标注来源；官方中文原文链接见本页页脚。
